PCYC Insider Trading
PCYC | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at PCYC provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2015-03-14 01:25 | 2015-03-11 | Soni Manmeet Singh | Officer - Chief Financial Officer | OPT+S | $254.24 | 27,514 | $6,995,261 | 54,611 | 0.0% |
| 2015-03-14 00:54 | 2015-03-11 | Zanganeh Maky | Officer - Chief Operating Officer | OPT+S | $254.11 | 30,000 | $7,623,444 | 225,312 | 0.0% |
| 2015-03-13 02:24 | 2015-03-12 | Tan Heow | Officer - Chief Quality&Tech Operations | OPT+S | $254.51 | 1,000 | $254,506 | 4,070 | 0.0% |
| 2014-11-18 00:19 | 2014-11-13 | Soni Manmeet Singh | Officer - Chief Financial Officer | OPT+S | $141.44 | 1,000 | $141,442 | 38,611 | 0.0% |
| 2014-11-18 00:30 | 2014-11-13 | Fardis Maria | Officer - Chief of Oncology Ops & Allian | OPT+S | $141.30 | 3,000 | $423,902 | 3,193 | 0.0% |
| 2014-11-13 02:07 | 2014-11-07 | Zanganeh Maky | Officer - Chief Operating Officer | OPT+S | $134.69 | 30,482 | $4,105,642 | 210,312 | 0.0% |
| 2014-11-11 02:28 | 2014-11-07 | Fardis Maria | Officer - Chief of Oncology Ops & Allian | OPT+S | $134.50 | 5,000 | $672,500 | 3,193 | 0.0% |
| 2014-11-11 02:30 | 2014-11-10 | Love Richard B | Officer - General Counsel | OPT+S | $133.87 | 1,500 | $200,805 | 205 | 0.0% |
| 2014-09-05 00:54 | 2014-09-03 | Zanganeh Maky | Officer - Chief Operating Officer | OPT+S | $121.75 | 12,000 | $1,460,980 | 210,311 | 0.0% |
| 2014-08-29 04:52 | 2014-08-27 | Love Richard B | Officer - General Counsel | OPT+S | $124.00 | 1,500 | $186,000 | 204 | 0.0% |
| 2014-08-15 21:41 | 2014-08-13 | Fardis Maria | Officer - Chief of Oncology Ops & Allian | OPT+S | $121.01 | 4,000 | $484,040 | 3,192 | 0.0% |
| 2014-08-14 00:27 | 2014-08-13 | Tan Heow | Officer - Chief Quality&Tech Operations | OPT+S | $123.58 | 10,000 | $1,235,808 | 1,873 | 0.0% |
| 2014-08-08 01:51 | 2014-08-07 | McGreivy Jesse | Officer - Chief Medical Officer | OPT+S | $120.92 | 34,062 | $4,118,610 | 0 | 0.0% |
| 2014-03-08 02:06 | 2014-03-05 | Fardis Maria | Officer - Chief of Oncology Ops & Allian | OPT+S | $140.50 | 3,000 | $421,504 | 2,988 | 0.0% |
| 2014-03-07 00:35 | 2014-03-05 | McGreivy Jesse | Officer - Chief Medical Officer | OPT+S | $139.66 | 6,563 | $916,599 | 0 | 0.0% |
| 2014-03-07 00:33 | 2014-03-04 | Sjovall Boultbee Paula S | Officer - EVP, Sales and Marketing | OPT+S | $138.22 | 20,000 | $2,764,446 | 1,739 | 0.0% |
| 2014-03-07 02:06 | 2014-03-05 | Hemmi Gregory | Officer - Sr. VP Chemical Operations | OPT+S | $140.00 | 15,000 | $2,100,033 | 38,004 | 0.0% |
| 2014-03-06 22:46 | 2014-03-04 | HALVORSON ERIC H | Director | OPT+S | $138.33 | 3,472 | $480,282 | 1,000 | 0.0% |
| 2014-03-06 04:15 | 2014-03-04 | Chang Betty Y | Officer - VP, Research/Biology | OPT+S | $137.97 | 17,500 | $2,414,484 | 3,754 | 0.0% |
| 2014-03-01 01:26 | 2014-02-25 | van den Broek Richard | Director | SELL | $146.63 | 78,835 | $11,559,655 | 29,610 | -72.7% |
| 2013-12-20 22:44 | 2013-12-19 | Tan Heow | Officer - Chief Quality&Tech Operations | OPT+S | $100.87 | 5,000 | $504,352 | 169 | 0.0% |
| 2013-12-19 03:24 | 2013-12-16 | Zanganeh Maky | Officer - Chief Operating Officer | SELL | $107.55 | 20,000 | $2,151,000 | 210,107 | -8.7% |
| 2013-12-19 03:30 | 2013-12-17 | Hemmi Gregory | Officer - VP Chemical Operations | OPT+S | $100.52 | 20,000 | $2,010,380 | 25,004 | 0.0% |
| 2013-12-17 03:13 | 2013-12-13 | Erdtmann Rainer M | Officer - Sr. VP, IR and Admin | OPT+S | $107.77 | 54,000 | $5,819,796 | 11,497 | 0.0% |
| 2013-06-07 01:46 | 2013-06-06 | Shearer Scott T | Officer - VP, Global Quality | OPT+S | $85.17 | 18,750 | $1,596,994 | 0 | 0.0% |
| 2013-06-01 03:02 | 2013-05-31 | McGreivy Jesse | Officer - VP, Clinical Science | OPT+S | $91.13 | 14,479 | $1,319,510 | 0 | 0.0% |
| 2013-06-01 03:03 | 2013-05-31 | Love Richard B | Officer - VP and General Counsel | OPT+S | $89.00 | 8,000 | $712,000 | 0 | 0.0% |
| 2013-06-01 03:06 | 2013-05-31 | Tan Heow | Officer - Chief of Technical Operations | OPT+S | $91.84 | 5,237 | $480,961 | 0 | 0.0% |
| 2013-06-01 03:15 | 2013-05-31 | Hemmi Gregory | Officer - VP Chemical Operations | OPT+S | $91.96 | 50,000 | $4,598,115 | 24,236 | 0.0% |
| 2013-02-12 03:19 | 2013-02-11 | Buggy Joseph J | Officer - VP, Research | OPT+S | $69.97 | 12,000 | $839,666 | 6,701 | 0.0% |
| 2013-02-06 03:08 | 2013-02-05 | Loury David J | Officer - Chief Scientific Officer | OPT+S | $70.58 | 20,000 | $1,411,510 | 325 | 0.0% |
| 2013-01-19 02:37 | 2013-01-17 | McGreivy Jesse | Officer - VP, Clinical Science | SELL | $67.29 | 583 | $39,229 | 0 | -100.0% |
| 2013-01-12 03:30 | 2013-01-11 | Hemmi Gregory | Officer - VP Chemical Operations | OPT+S | $67.11 | 5,000 | $335,550 | 22,992 | 0.0% |
| 2013-01-10 23:15 | 2013-01-09 | Loury David J | Officer - Chief Scientific Officer | OPT+S | $35.23 | 21,062 | $742,014 | 325 | 0.0% |
| 2013-01-10 03:05 | 2013-01-08 | Fardis Maria | Officer - EVP, Operations and Alliances | SELL | $65.00 | 2,500 | $162,500 | 976 | -71.9% |
| 2013-01-09 03:15 | 2013-01-08 | Loury David J | Officer - Chief Scientific Officer | OPT+S | $64.70 | 10,000 | $647,000 | 325 | 0.0% |
| 2013-01-08 04:23 | 2013-01-07 | Fardis Maria | Officer - EVP, Operations and Alliances | OPT+S | $64.20 | 3,500 | $224,700 | 3,476 | 0.0% |
| 2013-01-02 22:20 | 2012-12-31 | van den Broek Richard | Director | SELL | $58.50 | 7,171 | $419,476 | 108,445 | -6.2% |
| 2012-12-29 00:38 | 2012-12-27 | van den Broek Richard | Director | SELL | $57.99 | 30,285 | $1,756,363 | 108,445 | -21.8% |
| 2012-12-28 02:22 | 2012-12-26 | Hemmi Gregory | Officer - VP Chemical Operations | OPT+S | $59.20 | 13,000 | $769,625 | 22,992 | 0.0% |
| 2012-12-22 03:09 | 2012-12-20 | Loury David J | Officer - Chief Scientific Officer | OPT+S | $61.12 | 39,469 | $2,412,274 | 325 | 0.0% |
| 2012-12-19 03:05 | 2012-12-17 | Erdtmann Rainer M | Officer - VP, IR Education Training | OPT+S | $62.57 | 94,000 | $5,881,787 | 27,485 | 0.0% |
| 2012-12-18 03:10 | 2012-12-17 | Buggy Joseph J | Officer - VP, Research | OPT+S | $62.14 | 50,000 | $3,106,840 | 6,701 | 0.0% |
| 2012-05-21 23:03 | 2012-05-17 | Mehta Minesh | Director | OPT+S | $30.00 | 18,565 | $556,950 | 0 | 0.0% |
| 2012-02-16 03:36 | 2012-02-13 | Mehta Minesh | Director | OPT+S | $25.00 | 11,971 | $299,275 | 0 | 0.0% |
| 2012-02-15 01:53 | 2012-02-10 | Baker Biotech Capital (GP), LLC | 10% owner | BUY | $20.85 | 150,000 | $3,128,040 | 557,211 | +36.8% |
| 2012-02-08 04:58 | 2012-02-03 | Mehta Minesh | Director | OPT+S | $20.00 | 11,970 | $239,400 | 0 | 0.0% |
| 2012-01-27 02:12 | 2012-01-24 | Baker Biotech Capital (GP), LLC | 10% owner | BUY | $18.09 | 85,993 | $1,555,484 | 407,211 | +26.8% |
| 2012-01-27 02:12 | 2012-01-24 | Baker Brothers Life Sciences Capital (GP), LLC | 10% owner | BUY | $18.09 | 500,652 | $9,056,044 | 8,574,445 | +6.2% |
| 2012-01-27 02:09 | 2012-01-24 | 14159 capital (GP), LLC | 10% owner | BUY | $18.09 | 12,945 | $234,156 | 195,858 | +7.1% |
How to Interpret $PCYC Trades
Not every insider transaction in PCYC is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $PCYC shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for PCYC
Insider activity data for PCYC is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $PCYC, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.